TTNP Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to Titan Pharmaceuticals's net margin of --. Titan Pharmaceuticals's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Titan Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2650.49%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.3929 which suggests that it could grow by 512.46%. Given that Titan Pharmaceuticals has higher upside potential than Perspective Therapeutics, analysts believe Titan Pharmaceuticals is more attractive than Perspective Therapeutics.

Titan Pharmaceuticals has a beta of 1.249, which suggesting that the stock is 24.884% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

Titan Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Titan Pharmaceuticals pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Titan Pharmaceuticals quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Titan Pharmaceuticals's net income of -$790K is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Titan Pharmaceuticals's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Titan Pharmaceuticals is -- versus 15.21x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -- compared to Titan Pharmaceuticals's net margin of 12.11%. Titan Pharmaceuticals's return on equity of -- beat Electromed's return on equity of 15.91%.

Titan Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2650.49%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 66.14%. Given that Titan Pharmaceuticals has higher upside potential than Electromed, analysts believe Titan Pharmaceuticals is more attractive than Electromed.

Titan Pharmaceuticals has a beta of 1.249, which suggesting that the stock is 24.884% more volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.

Titan Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Titan Pharmaceuticals pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Titan Pharmaceuticals quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. Titan Pharmaceuticals's net income of -$790K is lower than Electromed's net income of $2M. Notably, Titan Pharmaceuticals's price-to-earnings ratio is -- while Electromed's PE ratio is 29.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Titan Pharmaceuticals is -- versus 3.34x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Titan Pharmaceuticals's net margin of 35.65%. Titan Pharmaceuticals's return on equity of -- beat Protalix BioTherapeutics's return on equity of 8.75%.

Titan Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2650.49%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 743.02%. Given that Titan Pharmaceuticals has higher upside potential than Protalix BioTherapeutics, analysts believe Titan Pharmaceuticals is more attractive than Protalix BioTherapeutics.

Titan Pharmaceuticals has a beta of 1.249, which suggesting that the stock is 24.884% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.048, suggesting its less volatile than the S&P 500 by 104.824%.

Titan Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Titan Pharmaceuticals pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Titan Pharmaceuticals quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Titan Pharmaceuticals's net income of -$790K is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Titan Pharmaceuticals's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 57.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Titan Pharmaceuticals is -- versus 2.67x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Titan Pharmaceuticals's net margin of -10.04%. Titan Pharmaceuticals's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.

Titan Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2650.49%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 246.78%. Given that Titan Pharmaceuticals has higher upside potential than Xtant Medical Holdings, analysts believe Titan Pharmaceuticals is more attractive than Xtant Medical Holdings.

Titan Pharmaceuticals has a beta of 1.249, which suggesting that the stock is 24.884% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

Titan Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Titan Pharmaceuticals pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Titan Pharmaceuticals quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Titan Pharmaceuticals's net income of -$790K is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Titan Pharmaceuticals's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Titan Pharmaceuticals is -- versus 0.58x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.